Skip to content
OpenCapital
Get started

Gilead Sciences GILD Product sales — Total revenues

Other product segments

Biktarvy
$3.36B+6.7%
Descovy
$807M+37.7%
Trodelvy
$402M+37.2%
Yescarta
$332M-14.0%
Sofosbuvir/Velpatasvir
$283M-18.2%
Genvoya
$264M-27.5%
Vemlidy
$237M-6.0%
Odefsey
$221M-21.4%
Yeztugo
$166M—
Veklury
$144M-52.3%
AmBisome
$138M-0.7%
Symtuza - Revenue share
$138M+21.1%
Livdelzi
$133M+233%
Other Liver Disease
$114M-5.8%
Tecartus
$75M-3.8%
Other HIV
$73M-19.8%
Other
$58M-17.1%
Royalty, contract and other revenues
$14M-74.1%

Similar metrics at other companies

Bristol-Myers Squibb logo
BMYNet product sales — Total Revenues
$11.17B+2.6%
Neurocrine Biosciences logo
NBIXNet product sales — Total revenues
$811M+43.9%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
Amgen logo
AMGNProduct sales — Total revenues
$8.22B+4.4%
Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%
Regeneron Pharmaceuticals logo
REGNProduct — Revenue
$1.53B+8.4%

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation

See full
Market cap$153.66B+23.8%
Enterprise value$168.2B+19.7%
P/E16.7×-4.1×
P/S5.2×+0.8×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp
FCF margin34.4%+0.1pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio2×+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's product sales — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's product sales — total revenues?
Gilead Sciences (GILD) reported product sales — total revenues of $6.95B in Q1 2026.
How has Gilead Sciences's product sales — total revenues changed year-over-year?
Gilead Sciences's product sales — total revenues increased by 5.0% year-over-year, from $6.61B to $6.95B.
What is the long-term trend for Gilead Sciences's product sales — total revenues?
Over 4 years (2021 to 2025), Gilead Sciences's product sales — total revenues has grown at a 1.7% compound annual growth rate (CAGR), from $27.01B to $28.91B.
What does product sales — total revenues mean?
This metric represents the total revenue generated from the sale of pharmaceutical products, excluding royalty, contract, and other non-product related income. It serves as the primary indicator of the company's commercial performance across its core therapeutic areas, including HIV, liver disease, and oncology. This figure reflects the market demand and pricing power of the company's portfolio of marketed therapies.